SGLT2i use linked to lower risk for neurodegenerative disease in T2DM
By
HealthDay News
Sep 18, 2024
A reduced risk for Alzheimer’s disease, vascular dementia and Parkinson’s disease was seen with SGLT2i use in type 2 diabetes.
No spike in schizophrenia, other diagnoses among people with dementia after feds crack down on antipsychotic...
By
Kimberly Marselas
Aug 28, 2024
Federal policies designed to reduce use of antipsychotic medications in nursing homes did not lead to clinically significantly higher rates of schizophrenia diagnoses among people living with dementia,...
Is Eli Lilly using ‘granfluencers’ to raise awareness of its Alzheimer’s med?
By
Marc Iskowitz
Sep 04, 2024
Here’s why older internet celebs — granfluencers — soon might be making rounds on the Alzheimer’s drug marketing scene.
Risk for dementia similar with SGLT2 inhibitors, dulaglutide in T2DM
Aug 26, 2024
The estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults.
CMS announces Alzheimer’s drug coverage policy, but ‘the devil is in the details,’ experts say
By
Kimberly Bonvissuto
Jun 01, 2023
A Thursday announcement by the Centers for Medicare & Medicaid Services regarding coverage of Alzheimer’s drugs is being met with skepticism by some industry advocates who say that “the devil is in...
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Inconsistent state regulations, staff training produce wide variations among states’ antipsychotic...
By
Kimberly Bonvissuto
Feb 28, 2023
Researchers are calling for a closer look at the use of antipsychotics among assisted living residents with dementia after a study found wide variations in prescribing patterns.
Future of promising Alzheimer’s treatment Leqembi could depend on access to data reporting, analysis:...
By
Aaron Dorman
Feb 16, 2024
Organizations must have clearer guidelines as to how data on lecanemab will be collected, pooled and studied, policy experts say.
Legislation aims to ensure ‘fair and accurate’ Alzheimer’s treatment coverage decisions
By
Kimberly Bonvissuto
Nov 21, 2023
Federal legislation that would prevent the federal government from imposing wide-reaching coverage restrictions on Alzheimer’s treatments was reintroduced last week, providing “fair and accurate”...
Feds’ antipsychotic drug reduction efforts in assisted living fail to produce success seen in nursing...
By
Alicia Lasek
Aug 23, 2022
A federal initiative to reduce antipsychotic prescribing in long-term care facilities failed to impact prescriptions in assisted living residents with dementia, the first study of its kind has found.